Phosphodiesterase‐4 Inhibition as a Potential Therapeutic Strategy in the Management of Obesity: a Review
Obesity Reviews · 2026-04 · 27 (4)
DOI: 10.1111/obr.70050 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Obesity Reviews, online erschienen am 21.12.2025. Verfasst von Aske Nicolai Høck und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Metabolic Research, Copenhagen University Hospital - Herlev and Gentofte Hospital, Hellerup, Denmark. Hauptthemen laut MEDLINE: Obesity, Phosphodiesterase 4 Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 112 Literaturangaben.
Abstract (Originalsprache)
Phosphodiesterase 4 (PDE4) inhibitors, originally developed for chronic inflammatory diseases, have shown unexpected metabolic benefits, including weight reduction and improved glycemic control in both preclinical and clinical studies. Weight loss typically occurs within the first 6–12 months of treatment and may be sustained over several years. While the underlying mechanisms remain incompletely understood, preclinical findings suggest that PDE4 inhibition may increase circulating levels of glucagon‐like peptide 1 (GLP‐1), enhance lipolysis and thermogenesis, and promote energy expenditure via stimulation of mitochondrial biogenesis. Additionally, PDE4 inhibitors reduce markers of systemic inflammation and may influence key obesity‐related comorbidities, including steatotic liver disease and impaired glucose metabolism. Despite these promising findings, the weight‐reducing potential of PDE4 inhibitors has not been systematically evaluated in individuals with obesity, and clinical studies to date have primarily involved individuals with inflammatory conditions. This review summarizes the current evidence on the metabolic effects of PDE4 inhibition, with a particular focus on body weight regulation. PDE4 inhibitors may represent a novel adjunctive pharmacological approach to obesity treatment, with potential to address multiple dimensions of obesity pathophysiology. However, dedicated trials in individuals with obesity are warranted to clarify their therapeutic efficacy and role in metabolic disease management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Clinical Metabolic Research, Copenhagen University Hospital - Herlev and Gentofte Hospital, Hellerup, Denmark.
- Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Clinical Research, Steno Diabetes Center Copenhagen, University of Copenhagen, Herlev, Denmark.
ORCID-Profile: Aske Nicolai Høck, Casper K Nielsen, Asger B Lund
Zitieren
APA
Høck, A. N., Olafsson, P. T., Gether, I. M., Grøndahl, M. F. G., Gyldenløve, M., Nielsen, C. K., & Lund, A. B. (2026). Phosphodiesterase‐4 Inhibition as a Potential Therapeutic Strategy in the Management of Obesity: a Review. Obesity Reviews, 27(4). https://doi.org/10.1111/obr.70050
Vancouver
Høck AN, Olafsson PT, Gether IM, Grøndahl MFG, Gyldenløve M, Nielsen CK, et al. Phosphodiesterase‐4 Inhibition as a Potential Therapeutic Strategy in the Management of Obesity: a Review. Obesity Reviews. 2026;27(4). doi:10.1111/obr.70050
BibTeX
@article{Hck2026,
author = {Høck, Aske Nicolai and Olafsson, Petur Thorri and Gether, Ida M and Grøndahl, Magnus F G and Gyldenløve, Mette and Nielsen, Casper K and Lund, Asger B},
title = {Phosphodiesterase‐4 Inhibition as a Potential Therapeutic Strategy in the Management of Obesity: a Review},
journal = {Obesity Reviews},
year = {2026},
volume = {27},
number = {4},
doi = {10.1111/obr.70050}
}
EUVIMED